The Latest Breaking News from Novo Nordisk

Founded in 1963, WeightWatchers faces bankruptcy with £1.25 billion ($1.6 billion) in debt, losing clients to drugs like Ozempic. Can the iconic programme survive?

Von der Leyen urged to take ‘rapid and radical action’ as president says tariffs on pharmaceuticals coming ‘shortly’

Novo Nordisk and Sanofi were among the companies threatening to hasten their exits to the U.S., as Trump promised pharma tariffs were coming “shortly.”

The Trump administration says it will raise Medicare Advantage payments sharply, good news for Humana, UnitedHealth and other health insurers.

The Trump administration finalized new Medicare and Medicaid policies late Friday, but left out weight-loss drugs. Eli Lilly stock skidded.

Trump’s tariffs on EU goods could slash exports by at least €85 billion, hitting autos and pharmaceuticals hardest. Germany, Denmark and Central Europe face sharp fallout, raising recession risks and forcing the ECB to consider rate cuts.

The market appears to be underestimating just how much these two companies can grow.

Novo Nordisk’s stocks experienced the sharpest monthly decline since July 2002 due to growing competition and several disappointing trial results. However, analysts remain optimistic about the shares, forecasting a potential price upside of up to 60% over the next 12 months.

Novo Nordisk will pay Lexicon Pharmaceuticals up to $1 billion to license its experimental obesity treatment.

Potential US tariffs on pharmaceuticals could set off a ripple effect that extends far beyond the immediate price hikes, as both the US and Europe heavily rely on each other.

The World Health Organization states that there were around 830 million people living with diabetes in 2022. More than half of them weren't taking diabetes medications, including insulin, likely due to access and cost issues.